BIOARTIFICIAL ORGANS III--TISSUE/IMMUNOISOLATION/TRIALS

生物人工器官 III——组织/免疫隔离/试验

• 批准号: 6216320
• 负责人: Alan D Cherrington
• 金额: $ 1.5万
• 依托单位: UNITED ENGINEERING FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6216320
• 关键词: biotechnology; meeting /conference /symposium; tissue engineering; travel

DESCRIPTION (taken from the application) A conference, "Bioartificial Organs III: Tissue Sourcing, Immunoisolation and Clinical Trials," is proposed for October 7-11, 2000 (to be held in Davos, Switzerland), to explore contemporary and emerging approaches of bioartificial organs as they interface with different fields. Biomedical applications and clinical trials will be highlighted. The intent is to make use of a fully interdisciplinary approach: chemistry, physical chemistry, materials science, polymer chemistry, cell culture, recombinant DNA technology, bioprocess engineering, and clinical sciences. Specifically, it will bring together three groups of professionals, who do not normally interact at a single conference: (1) materials and polymer scientists, (2) bioprocess engineers, and (3) medical professionals. The emphasis will be at the cross-section of these disciplines. The main coverage will be in the pancreas, liver, kidney, skin, dental and bone areas. The program will stress scientific fundamentals, evolve into applications and review the clinical status in each area. An attempt will be made to have approximately 2SM5/50 percentage split amongst the polymer, engineering and biological-medical categories. In addition, the organizers expect that the participants will come from academia, industry and clinical institutions on approximately even basis. The representation of a strong American contingency is critical to continue the multidisciplinary, which the bioartifical organ series has fostered. This is particularly acute In 2000 as a number of US universities, medical centers and firms am integrating with global partners or sponsors to move bioartificial organs from research to the clinic and marketplace as the parameters and metrics needed to evaluate new devices and therapies are being developed. The participation of regulators, executives and research directors from large small and medium sized enterprises and the inclusion of a pre-conference biotechnology investors summit complements the program. The conference will have a Gordon Conference style. The United Engineering Foundation (New York) will assume primary responsibilities for administration, logistics, mechanics, publicity, housing, and finance for the conference. The funding support is requested from NIH, NSF, Whitaker Fdn., Juvenile Diabetes Fdn., FNS (Switzerland), European Union and from other sources. The proceedings of the conference will be published as a peer reviewed volume (The New York Academy of Sciences).

描述（摘自申请表） 会议“生物人工器官 III：组织来源、免疫隔离和 临床试验”提议于 2000 年 10 月 7-11 日（在达沃斯举行， 瑞士），探索当代和新兴的生物人工方法 器官与不同领域的接口。生物医学应用和 临床试验将被重点关注。其目的是充分利用 跨学科方法：化学、物理化学、材料科学、 高分子化学、细胞培养、重组DNA技术、生物过程 工程和临床科学。具体来说，它将汇集三 通常不会在一次会议上互动的专业人士群体： (1) 材料和聚合物科学家，(2) 生物工艺工程师，以及 (3) 医学 专业人士。重点将放在这些学科的交叉领域。 主要覆盖胰腺、肝脏、肾脏、皮肤、牙齿和骨骼 地区。该计划将强调科学基础，演变成 申请并审查每个领域的临床状态。尝试将是 使聚合物中的比例约为 2SM5/50， 工程和生物医学类别。此外，主办方 预计参与者将来自学术界、工业界和临床界 机构在大致均匀的基础上。强势代表 美国的突发事件对于继续多学科研究至关重要， 生物人工器官系列已培育起来。这种情况在 2000 年尤其严重 许多美国大学、医疗中心和公司正在与全球接轨 合作伙伴或赞助商将生物人工器官从研究转移到临床 和市场作为评估新设备所需的参数和指标 并正在开发治疗方法。监管者、高管的参与 来自大型、中小型企业和研究机构的负责人 会前生物技术投资者峰会的加入是对 程序。会议将采用戈登会议风格。联合 工程基金会（纽约）将承担主要责任 行政、后勤、机械、宣传、住房和财务 会议。资金支持请求来自 NIH、NSF、Whitaker Fdn.、 青少年糖尿病 Fdn.、FNS（瑞士）、欧盟和其他国家 来源。会议记录将以同行评审形式出版 卷（纽约科学院）。